Nature Communications (Aug 2022)
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
- Neeltje van Doremalen,
- Jonathan E. Schulz,
- Danielle R. Adney,
- Taylor A. Saturday,
- Robert J. Fischer,
- Claude Kwe Yinda,
- Nazia Thakur,
- Joseph Newman,
- Marta Ulaszewska,
- Sandra Belij-Rammerstorfer,
- Greg Saturday,
- Alexandra J. Spencer,
- Dalan Bailey,
- Colin A. Russell,
- Sarah C. Gilbert,
- Teresa Lambe,
- Vincent J. Munster
Affiliations
- Neeltje van Doremalen
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Jonathan E. Schulz
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Danielle R. Adney
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Taylor A. Saturday
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Robert J. Fischer
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Claude Kwe Yinda
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Nazia Thakur
- Viral Glycoproteins Group, The Pirbright Institute, Pirbright
- Joseph Newman
- Viral Glycoproteins Group, The Pirbright Institute, Pirbright
- Marta Ulaszewska
- Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford
- Sandra Belij-Rammerstorfer
- Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford
- Greg Saturday
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- Alexandra J. Spencer
- Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford
- Dalan Bailey
- Viral Glycoproteins Group, The Pirbright Institute, Pirbright
- Colin A. Russell
- Laboratory of Applied Evolutionary Biology, Department of Medical Microbiology, Academic Medical Center, University of Amsterdam
- Sarah C. Gilbert
- Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford
- Teresa Lambe
- Oxford Vaccine Group, Department of Paediatrics, University of Oxford
- Vincent J. Munster
- Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
- DOI
- https://doi.org/10.1038/s41467-022-32248-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
Whilst the ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated efficacy against symptomatic disease, variants of concern (VOCs) with spike protein substitutions have led researchers to explore updating vaccines from ancestral spike protein. Authors use a Syrian hamster model to evaluate a vaccine encoding the spike protein of Beta VOC and assess efficacy against VOCs.
